<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bone</journal-id><journal-id journal-id-type="iso-abbrev">Bone</journal-id><journal-title-group><journal-title>Bone</journal-title></journal-title-group><issn pub-type="ppub">8756-3282</issn><issn pub-type="epub">1873-2763</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22023931</article-id><article-id pub-id-type="pmc">3459093</article-id><article-id pub-id-type="publisher-id">S8756-3282(11)01289-0</article-id><article-id pub-id-type="doi">10.1016/j.bone.2011.10.009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Full Length Article</subject></subj-group></article-categories><title-group><article-title>Follow-up study of Gambian children with rickets-like bone deformities and elevated plasma FGF23: Possible aetiological factors<sup><xref ref-type="fn" rid="d32e2064">&#x02606;</xref></sup><sup><xref ref-type="fn" rid="d32e2069">&#x02606;&#x02606;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Braithwaite</surname><given-names>Vickie</given-names></name><email>vickie.braithwaite@mrc-hnr.cam.ac.uk</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Jarjou</surname><given-names>Landing M.A.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Goldberg</surname><given-names>Gail R.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Helen</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Pettifor</surname><given-names>John M.</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Prentice</surname><given-names>Ann</given-names></name><email>ann.prentice@mrc-hnr.cam.ac.uk</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib></contrib-group><aff id="af0005"><label>a</label>MRC Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, UK</aff><aff id="af0010"><label>b</label>MRC Keneba, The Gambia</aff><aff id="af0015"><label>c</label>Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand and Chris Hani Baragwaneth Hospital, Johannesburg, South Africa</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: MRC Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, UK, CB1 9NL. Fax: +&#x000a0;44 1223 437515. <email>vickie.braithwaite@mrc-hnr.cam.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>1</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>1</month><year>2012</year></pub-date><volume>50</volume><issue>1</issue><fpage>218</fpage><lpage>225</lpage><history><date date-type="received"><day>14</day><month>7</month><year>2011</year></date><date date-type="rev-recd"><day>6</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Elsevier Inc.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">CC BY 3.0</ext-link> license</license-p></license></permissions><abstract><p>We have previously reported on a case-series of children (n&#x000a0;=&#x000a0;46) with suspected calcium-deficiency rickets who presented in The Gambia with rickets-like bone deformities. Biochemical analyses discounted vitamin D-deficiency as an aetiological factor but indicated a perturbation of Ca&#x02013;P metabolism involving low plasma phosphate and high circulating fibroblast growth factor-23 (FGF23) concentrations.</p><p>A follow-up study was conducted 5&#x000a0;years after presentation to investigate possible associated factors and characterise recovery. 35 children were investigated at follow-up (RFU). Clinical assessment of bone deformities, overnight fasted 2&#x000a0;h urine and blood samples, 2-day weighed dietary records and 24&#x000a0;h urine collections were obtained. Age- and season-matched data from children from the local community (LC) were used to calculate standard deviation scores (SDS) for RFU children.</p><p>None of the RFU children had radiological signs of active rickets. However, over half had residual leg deformities consistent with rickets. Dietary Ca intake (SDS-Ca&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.52 (0.98) <italic>p</italic>&#x000a0;=&#x000a0;0.04), dietary Ca/P ratio (SDS-Ca/P&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.80 (0.82) <italic>p</italic>&#x000a0;=&#x000a0;0.0008) and TmP:GFR (SDS-TmP:GFR&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.48 (0.81) <italic>p</italic>&#x000a0;=&#x000a0;0.04) were significantly lower in RFU children compared with LC children and circulating FGF23 concentration was elevated in 19% of RFU children. Furthermore an inverse relationship was seen between haemoglobin and FGF23 (R<sup>2</sup>&#x000a0;=&#x000a0;25.8, <italic>p</italic>&#x000a0;=&#x000a0;0.004).</p><p>This study has shown differences in biochemical and dietary profiles between Gambian children with a history of rickets-like bone deformities and children from the local community. This study provided evidence in support of the calcium deficiency hypothesis leading to urinary phosphate wasting and rickets and identified glomerular filtration rate and iron status as possible modulators of FGF23 metabolic pathways.</p></abstract><abstract abstract-type="graphical"><title>Highlights</title><p>&#x025ba; Low dietary calcium and eGFR in Gambian children with a history of rickets. &#x025ba; High FGF23 and urinary phosphate loss in Gambian children with a history of rickets. &#x025ba; Supports the calcium deficiency hypothesis as the aetiology of Gambian rickets. &#x025ba; Iron status may be involved in FGF23 metabolic pathways.</p></abstract><kwd-group><title>Keywords</title><kwd>Calcium</kwd><kwd>FGF23</kwd><kwd>Gambia</kwd><kwd>Kidney</kwd><kwd>Phosphate</kwd><kwd>Rickets</kwd></kwd-group></article-meta><notes><p>Edited by: Felicia Cosman</p></notes></front><body><sec sec-type="intro" id="s0005"><title>Introduction</title><p>There is increasing evidence of the occurrence of nutritional rickets in tropical countries where UVB-containing sunshine is abundant <xref rid="bb0005" ref-type="bibr">[1]</xref>. Studies of children with rickets in South Africa, Nigeria and The Gambia have reported vitamin D status above the range characteristic of vitamin D-deficiency rickets, as measured by plasma concentrations of 25-hydroxyvitamin D (25OHD) <xref rid="bb0010" ref-type="bibr">[2]</xref>. Low dietary calcium has been suggested as a possible explanation of this so-called &#x0201c;sunshine paradox&#x0201d;. Children with rickets in these countries have shown similar blood biochemical profiles with elevated 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D), parathyroid hormone (PTH) and total alkaline phosphatase (TALP) coupled with low plasma phosphate (P), normal to low plasma calcium (Ca) and a low dietary calcium intake <xref rid="bb0010 bb0015 bb0020" ref-type="bibr">[2&#x02013;4]</xref>.</p><p>A clinical case-series of 46 children with bone deformities consistent with rickets, conducted in The Gambia, indicated abnormally elevated concentrations of plasma fibroblast growth factor-23 (FGF23) in the majority of cases <xref rid="bb0010" ref-type="bibr">[2]</xref>. The hypothesis presented by Prentice et al. <xref rid="bb0010" ref-type="bibr">[2]</xref> linked a chronically low dietary calcium intake with an elevated plasma FGF23 concentration, resulting in excessive urinary phosphate loss and rickets (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). Following treatment with calcium and vitamin D, FGF23 concentrations (as measured with the Immutopics C-terminal FGF23 assay) remained consistently elevated over a 6&#x02013;12&#x000a0;month period, suggestive of a long-standing, chronic abnormality of phosphate regulation predisposing to rickets.</p><p>This follow-up study (RFU) on 35 of the 46 children from the original clinical case-series was conducted 5&#x000a0;years after initial presentation. Results from the RFU children were compared with age- and season-matched data from local community children (LC children).</p><p>This study was designed to test whether there were differences in dietary Ca intake, plasma FGF23 concentrations and urinary phosphate excretion between RFU and LC children and to identify other potential contributing pathologies to the aetiology of rickets, such as a perturbed vitamin D metabolism, impaired renal tubular function and poor liver function.</p></sec><sec sec-type="materials|methods" id="s0010"><title>Materials and methods</title><sec id="s0015"><title>Study approvals</title><p>Written informed consent was obtained from parents of the children involved in the study. Ethical approval was given by The Gambian Government/MRC Laboratories Joint Ethics Committee.</p></sec><sec id="s0020"><title>Children at follow-up (RFU children)</title><p>The 46 children in the original case-series were those who had attended clinics in MRC Fajara or MRC Keneba, The Gambia, between July 1999 and March 2002 with a presentation of leg deformities consistent with rickets <xref rid="bb0010" ref-type="bibr">[2]</xref>. Most were from the West Kiang province. Attempts were made to trace all these children for recruitment into the follow-up study. 35 children (12 female, 23 male, median (IQR) age 8.5 (2.6&#x000a0;years) were available and were included in RFU. The mean (SD) time interval between presentation and follow-up was 5.3 (0.5) years (range 4.2&#x02013;6.0&#x000a0;years). All measurements on these children were made during May to September 2006.</p></sec><sec id="s0025"><title>Local community children (LC children)</title><p>Age- and season-matched data were obtained from a community study which provided anthropometry, biochemistry, and dietary measurements from 30 Gambian children (LC children). This study was conducted during September and October 2007. The LC children were selected from the West Kiang Demographic Survey Database and were divided into three age bands ranging from 6 to 18&#x000a0;years, with the aim of recruiting a representative sample of 5 girls and 5 boys in each age band. West Kiang was divided into 5 geographical areas and 1 male child and 1 female child were randomly selected from each of the areas in the age bands 6.0&#x02013;9.9&#x000a0;years (AG1), 10.0&#x02013;13.9&#x000a0;years (AG2), and 14.0&#x02013;17.9 (AG3) years. Exclusion criteria included the current use of medication affecting bone mineral metabolism, intestinal, hepatic or renal function, and reported illness in the week preceding the study.</p></sec><sec id="s0030"><title>Characterisation of bone deformity and clinical assessment</title><p>A health check was carried out on RFU and LC children, paying particular attention to complaints or signs relating to bone, renal, intestinal and hepatic health. In addition for RFU children, a more detailed clinical assessment was conducted to identify the presence of any clinical signs and symptoms of rickets including seizures, frontal bossing, enlarged costochondral junctions, enlarged wrists or ankles, leg pain, difficulty walking and knock-knee, bow-leg or windswept deformity.</p><p>Anteroposterior radiographs and medical photographs were taken of both knees and both wrists of RFU children. Radiographs were scored by a consultant paediatrician (JMP) using a 10-point scoring system developed by Thacher et al. <xref rid="bb0025" ref-type="bibr">[5]</xref>. RFU children were diagnosed as having active rickets, on the basis of a Thacher radiographic score&#x000a0;&#x0003e;&#x000a0;1.5 or TALP&#x000a0;&#x0003e;&#x000a0;960&#x000a0;U/l or both, as in the original case-series <xref rid="bb0010" ref-type="bibr">[2]</xref>. RFU children were identified as having knock-knee, bow-leg or windswept deformity based on both the clinical examination and visual inspection of medical photographs. In order to investigate a genetic predisposition to rickets, the parent or guardian of RFU children were asked whether or not any other member of their family had signs of rickets-like deformities.</p></sec><sec id="s0035"><title>Anthropometry</title><p>Standard anthropometry was conducted including weight, standing height and sitting height. Weight was measured to 0.1&#x000a0;kg using a calibrated electronic scale (model HD-314, Tanita B.V., Hoofddorp, The Netherlands). Height was measured to the nearest mm using a portable stadiometer (Leicester Height Measure, SECA, Hamburg, Germany).</p></sec><sec id="s0040"><title>2-day weighed dietary record</title><p>In order to determine the calcium intake of the children a 2-day weighed dietary assessment was carried out by trained field-workers at the homes of the children. Coding of the dietary records was performed using The Gambian Food Composition Tables&#x000a0;<xref rid="bb0030" ref-type="bibr">[6]</xref> and an in-house analysis program adapted for use with Gambian foods was used to calculate nutrient intakes <xref rid="bb0035" ref-type="bibr">[7]</xref>. To consider the likelihood that calcium insufficiency was more prevalent in RFU children a yard stick of 200&#x000a0;mg of calcium a day was taken to represent the average bone calcium accretion rate across childhood <xref rid="bb0040" ref-type="bibr">[8]</xref>. The molar ratio of calcium/phosphorus (Ca/P) was determined using the molecular weight of calcium (40.08&#x000a0;g/mol) and phosphorus (30.97&#x000a0;g/mol). The Ca/P of 1 was used, as convention, to represent the optimal molar ratio of Ca/P in the diet <xref rid="bb0045" ref-type="bibr">[9]</xref>. Children were categorised as having a low dietary Ca/P if they had values &#x0003c;&#x000a0;0.33 <xref rid="bb0050" ref-type="bibr">[10]</xref>.</p></sec><sec id="s0045"><title>Fasting blood and 2&#x000a0;h and 24&#x000a0;h urine collections</title><p>An overnight-fasted, 2&#x000a0;h urine sample was collected between the hours of 07.00 and 09.00. Urinary dipstick tests (Multistix-SG, Bayer, Newbury, UK) for liver function (presence of bilirubin and urobilinogen) and kidney function (presence of protein, haemoglobin, glucose, and leucocyte esterase) were performed on fresh 2&#x000a0;h urine collections. Acidified (HCl 10&#x000a0;&#x003bc;l/ml, laboratory reagent grade SD 1.18, Fisher Scientific) and non-acidified urine aliquots were stored at &#x02212;&#x000a0;20&#x000a0;&#x000b0;C and then later transported frozen on dry ice to MRC HNR, Cambridge, UK where they were stored at &#x02212;&#x000a0;80&#x000a0;&#x000b0;C until analysis.</p><p>A fasting, antecubital venous blood sample (5&#x02013;15&#x000a0;ml according to the age of the child) was collected 1&#x000a0;h after the start of the 2&#x000a0;h urine collection and was transferred to pre-cooled lithium heparin (LiHep) and EDTA-coated tubes. Blood ionised calcium (<italic>i</italic>Ca) and haemoglobin (Hb) were measured in the LiHep sample (ABL77, Radiometer Medical, USA) within 10&#x000a0;min and pH 7.4 corrected values for <italic>i</italic>Ca were used. The remainder of the blood was separated by centrifugation at 4&#x000a0;&#x000b0;C within 45&#x000a0;min and frozen at &#x02212;&#x000a0;20&#x000a0;&#x000b0;C, and later transported frozen on dry ice to MRC HNR, Cambridge, UK where it was stored at &#x02212;&#x000a0;80&#x000a0;&#x000b0;C until analysis.</p><p>24&#x000a0;h urine collections from the children were supervised by trained field-workers at their homes. Urine was directly voided into acid-washed plastic urine containers and was kept in a cool box with frozen ice-packs until transfer to laboratory refrigerators. At the end of 24&#x000a0;h, all urine provided by each child was pooled, total volume measured and then processed as described for the 2&#x000a0;h urine collection.</p></sec><sec id="s0050"><title>Biochemical analysis</title><p>The samples were analysed for markers of vitamin D, calcium and phosphate metabolism, and of renal and hepatic function using commercially available methods according to the manufacturers' instructions. EDTA-plasma was used for the analysis of intact PTH and C-terminal FGF23; LiHep-plasma was used for other analyses. PTH was measured by immunoradiometric assay (DiaSorin Ltd, Wokingham, Berks, UK) and FGF23 was analysed using a 2nd generation C-terminal, two-site enzyme-linked immunosorbant assay (Immutopics Inc., San Clemente, CA). For FGF23 the manufacturer's upper limit of the reference range of 125&#x000a0;RU/ml was used as a cut-off of normality. Plasma 25OHD and 1,25(OH)<sub>2</sub>D were measured by radioimmunoassay (DiaSorin, Stillwater, MN, USA and IDS, Tyne and Wear, UK respectively). For 25OHD, &#x0003c;&#x000a0;25&#x000a0;nmol/l was taken as an indicator of increased risk of vitamin D deficiency rickets <xref rid="bb0055" ref-type="bibr">[11]</xref>. Cyclic AMP (cAMP) was measured using the tetramethylbenzide method (R&#x00026;D Systems-ELISA). The following colorimetric methods (Koni Analyser 20i, Finland) were used to determine plasma analytes: total calcium (TCa), arsenazo III; P, ammonium molybdate: creatinine (Cr), Jaffe; albumin, bromocresol purple; TALP, p-nitrophenol; magnesium (Mg), xylidyl blue I; cystatin C (Cys C), immunoprecipitation; bilirubin, diazo coupling; and aspartase transaminase (AST), enzymatic.</p><p>Acidified urine was used to determine urinary (<italic>u</italic>) <italic>u</italic>Ca, <italic>u</italic>P, <italic>u</italic>Cr, <italic>u</italic>cAMP and <italic>u</italic>Mg employing the same colorimetric methods as for plasma. Standards used in urinary assays were acidified prior to use. Urinary concentrations were expressed in moles per unit time.</p><p>Assay accuracy and precision were monitored across the working range of the assays using reference materials provided by external quality assurance schemes (NEQAS, Department of Clinical Biochemistry, Royal Infirmary, Edinburgh, UK: DEQAS, Endocrine/Oncology Laboratory, Charing Cross Hospital, London, UK) or purchased commercially (Roche Human Control, Roche Diagnostic Ltd, Lewes, East Sussex, UK) and kit controls supplied by the manufacturer. In addition, an aliquot of a pooled plasma sample was assayed in each batch to monitor possible drift over time and to provide running quality assurance for analytes where no external reference material was available.</p></sec><sec id="s0055"><title>Statistical analysis and calculations</title><p>Statistical analysis including multiple regression, 2-sample Student's&#x000a0;t-tests and chi-square tests was performed using DataDesk 6.1.1 (Data Description Inc, Ithaca, NY); p&#x000a0;&#x02264;&#x000a0;0.05 was considered statistically significant. Normally distributed data are presented as mean and 1&#x000a0;SD, positively skewed distribution of data is presented as geometric mean and (&#x02212;&#x000a0;1&#x000a0;SD, +&#x000a0;1&#x000a0;SD) obtained from the antilog of mean (1&#x000a0;SD) for the logged values. Variables with positively skewed distributions were transformed to natural logarithms before further statistical analysis.</p><p>Regression analysis of data from the LC children was used to assess the relationships between age (as a continuous variable) and sex with each variable (anthropometric, biochemical or dietary). Sex was not a significant factor in predicting any of the variables with the exception of creatinine, and therefore was not included in the models presented in this paper. However, 25OHD, iCa, P, FGF23, 1,25(OH)<sub>2</sub>D, PTH, Cys C, Cr and albumin were influenced by age. Age-adjustments were therefore included for these variables. To adjust for age in linear regression, age was added as an independent variable in all models.</p><p>Standard deviation scores (SDS) were calculated for all variables to enable age-adjusted comparisons to be made between RFU and LC children. As the data from RFU and LC children were collected at the similar time of year, the SDS were, by definition, adjusted for season. SDS was calculated in the following way: [(value <sub>RFU</sub>&#x000a0;&#x02212;&#x000a0;mean<sub>LC</sub>)&#x000a0;/&#x000a0;SD<sub>LC</sub>] within the specific age bands as indicated in <xref rid="s0025" ref-type="sec">Local community children (LC children)</xref>. Group differences between RFU and LC children were determined by 2-sample Student's&#x000a0;t-tests using SDS values. This method allowed for the small sample size of LC children in each age band and therefore was a more conservative estimate of the significance of group differences than considering the significance of the deviation of the SDS of RFU children from zero. The sample size of 35 RFU and 30 LC children, meant that the study was able to detect significant group differences in SDS of approximately 0.66 SD (two thirds of a standard deviation) or greater, at p&#x000a0;&#x02264;&#x000a0;0.05 with 80% power.</p><p>TCa was corrected for albumin (corr-Ca) by normalising to an albumin concentration of 36&#x000a0;g/l using a correction factor of 0.016&#x000a0;mmol TCa/g albumin. This correction factor was calculated from the slope of the relationship between TCa and albumin in LC children <xref rid="bb0060" ref-type="bibr">[12]</xref>.</p><p>Urinary excretion and clearance data were corrected for age-appropriate body surface area (BSA<sub>age</sub>). BSA was calculated using the Mosteller formula BSA&#x000a0;=&#x000a0;&#x0221a;((ht (cm)&#x000a0;&#x000d7;&#x000a0;wt (kg))&#x000a0;/&#x000a0;3600) m<sup>2</sup>
<xref rid="bb0065" ref-type="bibr">[13]</xref> and then corrected to the age-appropriate mean BSA for each LC AG (AG1: 0.81 (0.12) m<sup>2</sup>, AG2: 1.16 (0.17) m<sup>2</sup>, AG3: 1.38 (0.16) m<sup>2</sup>). As no difference was found between BSA<sub>age</sub> when calculated with standing height or sitting height, standing height was used for all BSA<sub>age</sub> adjustments.</p><p>Estimated glomerular filtration rate (eGFR ml/min), was derived in four ways from equations which use plasma Cys C and/or plasma Cr as markers.</p><p>The Cys C based equations include: 1) Cys C-eGFR&#x000a0;=&#x000a0;[74.835&#x000a0;/&#x000a0;(Cys C(mg/l)<sup>1/0.75</sup>)] ml/min <xref rid="bb0070" ref-type="bibr">[14]</xref> and 2) Counahn&#x02013;Barret ( C-B-eGFR)&#x000a0;=&#x000a0;[39.1 [ht (m)&#x000a0;/&#x000a0;Cr (mg/dl)]<sup>0.516</sup>&#x000a0;&#x000d7;&#x000a0;[1.8&#x000a0;/&#x000a0;Cys C (mg/l)]<sup>0.294</sup>[30&#x000a0;/&#x000a0;urea (mg/dl)]<sup>0.169</sup>&#x000a0;&#x000d7;&#x000a0;[1.099]<sup>male</sup> [ht (m)&#x000a0;/&#x000a0;1.4]<sup>0.188</sup>] <xref rid="bb0075" ref-type="bibr">[15]</xref>.</p><p>The Cr based equations include: 3) Schwarz-eGFR&#x000a0;=&#x000a0;[k&#x000a0;&#x000d7;&#x000a0;ht(cm)&#x000a0;/&#x000a0;Cr (&#x000b5;mol/l)], with k&#x000a0;=&#x000a0;0.55 (children, ages 2&#x02013;12&#x000a0;years and girls ages 13&#x02013;21&#x000a0;years) and k&#x000a0;=&#x000a0;0.70 for boys ages 13&#x02013;21&#x000a0;years) <xref rid="bb0080" ref-type="bibr">[16]</xref>; and 4) creatinine clearance (C<sub>Cr</sub>)&#x000a0;=&#x000a0;[(<italic>u</italic>Cr mmol/l&#x000a0;&#x000d7;&#x000a0;<italic>u</italic>Volume ml/min)&#x000a0;/&#x000a0;<italic>p</italic>Cr mmol/l].</p><p>Renal handling of Ca and P was investigated using urinary excretion expressed both as mmol per unit time (2&#x000a0;h and 24&#x000a0;h for <italic>u</italic>Ca, and <italic>u</italic>P) and as mineral clearance (C<sub>Ca</sub> and C<sub>P</sub>). C<sub>Ca</sub> and C<sub>P</sub> were calculated using the following equation: [(<italic>u</italic>Ca or <italic>u</italic>P mmol/l&#x000a0;&#x000d7;&#x000a0;urine volume l/h)&#x000a0;/&#x000a0;(plasma TCa or P mmol/l)] <xref rid="bb0085" ref-type="bibr">[17]</xref>. Tubular maximal reabsorption of phosphate (TmP:GFR) (mmol/l) was determined in the following way: Tubular reabsorption of phosphate (TRP)&#x000a0;=&#x000a0;1&#x000a0;&#x02212;&#x000a0;{(<italic>u</italic>P/P)&#x000a0;&#x000d7;&#x000a0;(Cr/<italic>u</italic>Cr)}, if TRP&#x000a0;&#x0003c;&#x000a0;0.86 then TmP:GFR&#x000a0;=&#x000a0;TRP&#x000a0;&#x000d7;&#x000a0;P mmol/l, if TRP&#x000a0;&#x0003e;&#x000a0;0.86 then TmP:GFR&#x000a0;=&#x000a0;(0.3&#x000a0;&#x000d7;&#x000a0;TRP&#x000a0;/&#x000a0;{1&#x000a0;&#x02212;&#x000a0;(0.8&#x000a0;&#x000d7;&#x000a0;TRP)})&#x000a0;&#x000d7;&#x000a0;P mmol/l <xref rid="bb0090" ref-type="bibr">[18]</xref>.</p></sec></sec><sec sec-type="results" id="s0060"><title>Results</title><sec id="s0065"><title>Children lost to follow-up</title><p>Of the 46 subjects in the original study, 11 were lost to follow-up; one had died, 4 had moved away from the region, and 6 were not traceable. There was no significant difference in age, sex or proportion with active rickets at presentation between children in RFU and those lost to follow-up. There was also no significant difference in plasma FGF23, 25OHD, 1,25(OH)<sub>2</sub>D, TCa, P, TALP or PTH at presentation between subjects followed-up in RFU and those who were not (data not shown).</p></sec><sec id="s0070"><title>Characterisation of RFU children</title><p>The median age of the 35 RFU children was 8.5 (IQR 2.6) years; 66% were male and 34% female. Nine of the 13 subjects with active rickets in the original study were followed up. There was a trend for RFU children to be heavier than LC children, although not significantly (SDS-weight&#x000a0;=&#x000a0;0.41 (0.79) p&#x000a0;=&#x000a0;0.07). There was no significant difference in standing height, sitting height or BSA between RFU and LC children (SDS-standing height&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.17 (0.81) p&#x000a0;=&#x000a0;0.4; SDS-sitting height&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.06 (0.7) p&#x000a0;=&#x000a0;0.8; SDS-BSA&#x000a0;=&#x000a0;0.28 (0.81) p&#x000a0;=&#x000a0;0.22). None of the RFU children had active rickets as determined by raised TALP and/or Thacher radiographic scoring. However, 19 (54%) had visible lower limb deformities; 10 (29%) had knock-knees, 8 (23%) had bow-legs and 1 (3%) had windswept deformity. Of those with leg deformities, 4 (11%) had switched from bow-legs to knock-knees since presentation, 1 (3%) experienced pain while walking and 2 (6%) experienced pain while running.</p><p>With the exception of two RFU children who were siblings, the parents/guardians of RFU children did not report any other cases of rickets-like bone deformities in their family.</p></sec><sec id="s0075"><title>Dietary intake</title><p><xref rid="t0005" ref-type="table">Table&#x000a0;1</xref> presents the results from the 2-day dietary assessment. Daily calcium intake was significantly lower in RFU than LC children. The mean calcium intake of RFU children was 188 (124, 283) mg/day compared to 305 (167, 556) mg/day in the LC children. 19 (56%) of the RFU children had calcium intakes of &#x02264;&#x000a0;200&#x000a0;mg/day compared with 7 (29%) of LC children (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;6.51, p&#x000a0;=&#x000a0;0.005). Calcium intake increased with age but was consistently lower in RFU than LC children across the age bands.</p><p>There was no obvious difference in dietary habits between the two groups but a possible indication that there was a lower consumption of milk in RFU children. Three (8%) RFU children consumed milk (added to porridge at breakfast) on one (<italic>n&#x000a0;=&#x000a0;2)</italic> or both days (<italic>n&#x000a0;=&#x000a0;1)</italic> of the dietary assessment compared with six (20%) LC children who consumed milk (added to porridge at breakfast) on one (<italic>n&#x000a0;=&#x000a0;2</italic>) or both days (<italic>n&#x000a0;=&#x000a0;4</italic>) (difference in number of records: &#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;4.59, p&#x000a0;=&#x000a0;0.02). The mean portion of milk per day (g) was significantly lower in RFU children compared to LC children (56 (67) g and 170 (90) g respectively, p&#x000a0;=&#x000a0;0.02). The total mean (g) of milk consumed over two days was significantly lower in RFU children compared to LC children (76 (56) g and 307 (213) g respectively, p&#x000a0;=&#x000a0;0.04). RFU children who consumed milk were significantly younger than LC children (9.0 (1.52) and 13.1 (1.7) years respectively, p&#x000a0;=&#x000a0;0.02).</p><p>LC children in AG2 (10.0&#x02013;13.9&#x000a0;years) had a higher daily calcium intake compared to AG3 (14.0&#x02013;18.0&#x000a0;years) due to the fact that 5 of the 6 milk drinkers were in AG2. Daily calcium intake remained significantly lower in RFU than LC children when the milk drinkers in LC AG2 were excluded (SDS-calcium&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.56 (1.10) p&#x000a0;=&#x000a0;0.04). None of the RFU or LC children had dietary Ca/P&#x000a0;&#x02265;&#x000a0;1.0; the highest was 0.5 and 0.7&#x000a0;mol/mol in RFU and LC children respectively. The molar dietary ratio of Ca/P was significantly lower in RFU children compared with LC children but phosphorus intake was similar in the two groups. RFU children had a greater prevalence of low Ca/P with 77% having a Ca/P&#x000a0;&#x0003c;&#x000a0;0.33 compared with 41% of LC children (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;8.52, p&#x000a0;=&#x000a0;0.002).</p></sec><sec id="s0080"><title>Biochemical profile</title><p>All RFU and LC children had plasma 25OHD concentrations &#x0003e;&#x000a0;25&#x000a0;nmol/l. RFU children had significantly lower Corr-Ca concentrations and tended to have lower iCa and P concentrations compared to LC children (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>). The mean group differences between RFU and LC children for FGF23, 1,25OH<sub>2</sub>D and TALP were respectively 0.54 SDS, 0.20 SDS and 0.21 SDS greater in RFU children. Although these differences were below the minimum difference detectable as significant given the sample sizes of the study, this pattern paralleled that seen in the original study of children with rickets (non-active) but was less pronounced.</p><p>The range of FGF23 concentrations was much wider in RFU children than in LC children due to a pronounced positive skew; 3.5&#x02013;3091.2&#x000a0;RU/ml and 13.3&#x02013;421.4&#x000a0;RU/ml respectively (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>A). Regression analysis indicated a significant correlation between plasma FGF23 at presentation <xref rid="bb0010" ref-type="bibr">[2]</xref> and at follow-up (R<sup>2</sup>&#x000a0;=&#x000a0;56.5%, p&#x000a0;&#x02264;&#x000a0;0.0001) (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>B). 19% of RFU children (<italic>n&#x000a0;=&#x000a0;6</italic>) had FGF23 concentrations&#x000a0;&#x0003e;&#x000a0;125&#x000a0;RU/ml compared to 3% of LC children (<italic>n&#x000a0;=&#x000a0;1</italic>) (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;3.67, p&#x000a0;=&#x000a0;0.03). Although FGF23 concentration decreased from presentation to follow up, children with grossly elevated FGF23 concentrations at presentation remained grossly elevated at follow-up (<italic>n&#x000a0;=&#x000a0;3</italic>).</p></sec><sec id="s0085"><title>Liver and kidney function; eGFR and mineral excretion</title><p>Urinary dipstick tests for the presence of bilirubin and urobilinogen as markers of liver malfunction were negative for all children in both groups. Plasma concentrations of albumin and AST were significantly elevated and plasma bilirubin significantly lower in RFU than LC children (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>).</p><p>Urinary dipstick tests for the presence of protein, glucose, Hb and leucocyte esterase as markers of kidney disease or inflammation were negative for all children in both groups.</p><p>eGFR as calculated with Cys C based equations (Cys C-eGFR and C-B-eGFR) was significantly lower in RFU than LC children. However, no significant difference was seen in eGFR when using Cr based equations (C<sub>Cr</sub> or the Schwarz-eGFR) (<xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>).</p><p>Mineral handling calculations indicated that TmP:GFR was significantly lower in RFU than LC children and that <italic>u</italic>P excretion over a 24&#x000a0;h period was significantly higher in RFU than LC children. This increase was also reflected in a higher C<sub>P</sub> over a 24&#x000a0;h period. <italic>u</italic>Ca excretion excretion over 24&#x000a0;h and C<sub>Ca</sub> were lower in RFU than LC children (<xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>).</p></sec><sec id="s0090"><title>Predictors of FGF23</title><p>Plasma FGF23 concentration was not correlated with plasma P and 1,25(OH)<sub>2</sub>D or TmP:GFR in either the RFU or LC children. However, Hb concentration was inversely correlated with FGF23 concentration in RFU children (<xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>). There was no significant difference in Hb concentration between RFU and LC children (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>) but there was a significant Hb&#x000a0;&#x000d7;&#x000a0;group interaction (<italic>p</italic>&#x000a0;=&#x000a0;0.003), indicating a difference in the slope in the relationship between Hb and FGF23 between the two groups.</p></sec><sec id="s0095"><title>RFU children with lasting lower-limb deformities</title><p>The median age of the 19 (54%) RFU children with and the 16 (46%) without lasting leg deformities was 8.4 (IQR 2.7) and 8.6 (IQR 2.7) respectively. There was no significant difference in age, standing height, sitting height or weight between RFU children with or without lasting limb deformities. However, those with lasting leg deformities tended to be male (F/M&#x000a0;=&#x000a0;4/15) compared to those without lasting leg deformities (F/M&#x000a0;=&#x000a0;8/8) (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;3.23, p&#x000a0;=&#x000a0;0.04). There was no difference in dietary profile between RFU children with and without lasting limb deformities. Those with leg deformities had significantly higher 1,25(OH)<sub>2</sub>D and significantly lower Cys C-eGFR than those whose deformities had recovered (<xref rid="t0020" ref-type="table">Table&#x000a0;4</xref>). There was no significant difference in Hb concentration (<xref rid="t0020" ref-type="table">Table&#x000a0;4</xref>) or in the relationship between Hb and FGF23 in RFU children with or without leg deformities (data not shown).</p></sec></sec><sec sec-type="discussion" id="s0100"><title>Discussion</title><p>The Republic of The Gambia (latitude 13&#x000b0;N) in West Africa has a hot and dry tropical climate with a single wet season from June to October. There is abundant UVB-containing sunshine throughout the year and a lifestyle that does not restrict sunshine exposure but, despite the low prevalence of vitamin D deficiency within the population, there are cases of rickets <xref rid="bb0010" ref-type="bibr">[2]</xref>.</p><p>The original clinical case series of Gambian children with bone deformities consistent with rickets indicated that 70% of the patients had elevated FGF23 concentrations <xref rid="bb0010" ref-type="bibr">[2]</xref>. This detailed follow-up study conducted 5&#x000a0;years after initial presentation was designed to investigate possible characteristics underlying the aetiology of rickets and long-term abnormalities in bone and mineral metabolism. This study has provided evidence of low calcium intake, persistently elevated FGF23 and increased urinary P excretion. Additionally, this study has not found gross abnormalities suggestive of other potential pathologies contributing to the aetiology of rickets such as a perturbed vitamin D metabolism, renal tubular pathology, or compromised hepatic function. Although there was no evidence from family histories to suggest that these children had a latent genetic disorder of renal phosphate wastage that was unmasked by their low calcium intake, the possibility that they had a genetic predisposition cannot be ruled out.</p><p>The rural Gambian diet consists of a high proportion of rice and leaf-based sauces; meat and fish are consumed in relatively small amounts and dairy produce rarely features <xref rid="bb0095" ref-type="bibr">[19]</xref>. The habitual dietary intake of calcium in The Gambia is very low, averaging around 350&#x000a0;mg/day in adults <xref rid="bb0010" ref-type="bibr">[2]</xref>, the greatest contributors being from leaves and fruit of the baobab tree <xref rid="bb0095" ref-type="bibr">[19]</xref>. Dietary phosphorus is found in a wide variety of foods and as a result is usually plentiful in a typical Gambian diet <xref rid="bb0095" ref-type="bibr">[19]</xref>. This follow-up study has indicated that, even 5&#x000a0;years post presentation, the RFU children had a significantly lower dietary calcium intake compared to LC children which may be linked to a lower consumption of milk. This may indicate that RFU children may have had an inadequate calcium supply which may have contributed to their poorer skeletal health. Additionally RFU children had a significantly lower calcium-to-phosphorus ratio compared to LC children.</p><p>This study also demonstrated that FGF23 concentration has remained above the upper limit of the reference range in 19% of RFU children. Interestingly an elevated FGF23 concentration was also seen in one apparently healthy LC child. Furthermore, urinary phosphate excretion was higher and TmP:GFR was lower in RFU children. Contrary to the original study and despite a greater urinary phosphate excretion in RFU children, circulating P was within the normal range. Furthermore, there was no correlation between FGF23 and P in the RFU children. It is possible that FGF23 no longer regulated P homeostasis in these children either due to a) end-organ resistance to FGF23 or b) a large proportion of inactive C-terminal FGF23 fragments. Alternatively, it is possible that a proportionally greater supply of phosphorus from the gastrointestinal tract enabled the RFU children to maintain normo-phosphataemia in the face of elevated FGF23. This would be explained by a) the higher intestinal P availability and b) an upregulation of the fractional Ca and P absorption due to a low Ca dietary intake <xref rid="bb0100" ref-type="bibr">[20]</xref>. It is thus possible that the absorption of phosphorus was greater in RFU children.</p><p>We have identified that eGFR was significantly lower in RFU children compared with LC children when measured by Cys C derived equations. However, when using Cr based eGFR equations no significant differences between the groups were seen. This may be explained by the fact that although both Cys C and Cr are filtered by the glomerulus, a portion of Cr is also secreted by the tubules and excreted in urine <xref rid="bb0105" ref-type="bibr">[21]</xref>. When glomerular filtration is compromised, tubular secretion of Cr is increased in order to maintain normal plasma Cr concentration <xref rid="bb0110" ref-type="bibr">[22]</xref>. The results therefore suggest that RFU children had a less efficient glomerular filtration rate and a compensatory increase in tubular secretion of Cr. An alternative possibility is that the RFU children had a lower lean body mass/weight ratio than LC children resulting in a lower daily release of Cr into the circulation which may have obscured the lower GFR. Cys C is regarded as a more sensitive marker for the calculation of eGFR in children because of problems of interpreting those based on Cr <xref rid="bb0115" ref-type="bibr">[23]</xref>. The data therefore suggest that RFU children had a less efficient GFR but not sufficient to cause clinical problems.</p><p>Both the original and follow-up studies measured FGF23 concentrations using the Immutopics C-terminal FGF23 assay which detects both the intact FGF23 hormone and its C-terminal fragments. In the case of RFU it is likely that the elevated FGF23 was reflecting both an increased production of intact and biologically active FGF23 hormone and possibly a greater proportion of presumed inactive C-terminal fragments.</p><p>Another intriguing finding was the inverse correlation between Hb and FGF23 in RFU children. As iron deficiency anaemia is endemic in The Gambia <xref rid="bb0120" ref-type="bibr">[24]</xref> a lower Hb in these children is likely to imply a lower iron status. A finding of a relationship between Hb and FGF23 therefore supports previous suggestions of the involvement of iron in FGF23 metabolic pathways <xref rid="bb0125 bb0130" ref-type="bibr">[25,26]</xref>. Researchers have hypothesised that iron is required for the clearance of FGF23 fragments by the kidney and also that iron may inhibit the cleavage of intact FGF23 <xref rid="bb0125" ref-type="bibr">[25]</xref>. It is possible that the combination of low iron status and lower eGFR may have resulted in greater amounts of circulating FGF23 fragments in RFU children, due to less efficient clearance by the kidney and/or an increased production of C-terminal fragments.</p><p>None of the RFU children had radiological signs of active rickets but only half of the children had recovered from their lower-limb deformities. Those with persisting deformities were of similar age but had higher 1,25(OH)<sub>2</sub>D and lower Cys C-eGFR when compared with those who had recovered. A study carried out in Nigeria suggested incomplete distal renal tubular acidosis (idRTA) as a possible cause of differing rates of recovery from rickets-like-deformities <xref rid="bb0135" ref-type="bibr">[27]</xref>. However, it is an unlikely explanation in this Gambian study as idRTA is characteristically accompanied by high <italic>uCa</italic> which was not seen in the RFU children.</p><p>In summary the dietary and biochemical profile of the RFU children is in keeping with the calcium deficiency hypothesis; chronically low Ca supply resulting in a 1,25(OH)<sub>2</sub>D-driven increase in FGF23 production, and decreased TmP:GFR and consequent excessive loss of phosphate in the urine. Additionally, this study has suggested the involvement of GFR and iron status in FGF23 metabolic pathways.</p></sec><sec id="s0105"><title>Conflicts of interest</title><p>None of the authors has a conflict of interest with respect to the study reported in this paper.</p></sec></body><back><ref-list><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Thacher</surname><given-names>T.</given-names></name><name><surname>Fischer</surname><given-names>P.R.</given-names></name><name><surname>Strand</surname><given-names>M.A.</given-names></name><name><surname>Pettifor</surname><given-names>J.</given-names></name></person-group><article-title>Nutritional rickets around the world: causes and future directions</article-title><source>Ann Trop Paediatr</source><volume>26</volume><year>2006</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">16494699</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>A.</given-names></name><name><surname>Ceesay</surname><given-names>M.</given-names></name><name><surname>Nigdikar</surname><given-names>S.</given-names></name><name><surname>Allen</surname><given-names>S.J.</given-names></name><name><surname>Pettifor</surname><given-names>J.M.</given-names></name></person-group><article-title>FGF23 is elevated in Gambian children with rickets</article-title><source>Bone</source><volume>42</volume><year>2008</year><fpage>788</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">18234575</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Pettifor</surname><given-names>J.M.</given-names></name><name><surname>Ross</surname><given-names>P.</given-names></name><name><surname>Travers</surname><given-names>R.</given-names></name><name><surname>Glorieux</surname><given-names>F.H.</given-names></name><name><surname>Deluca</surname><given-names>H.</given-names></name></person-group><article-title>Dietary calcium deficiency: a syndrome associated with bone deformities and elevated serum 1,25-dihydroxyvitamin D concentrations</article-title><source>Metab Bone Dis Relat Res</source><volume>2</volume><year>1981</year><fpage>301</fpage><lpage>305</lpage></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Pfitzner</surname><given-names>M.</given-names></name><name><surname>Thacher</surname><given-names>T.</given-names></name><name><surname>Pettifor</surname><given-names>J.M.</given-names></name><name><surname>Zoakah</surname><given-names>A.</given-names></name><name><surname>Lawson</surname><given-names>J.</given-names></name><name><surname>Isichei</surname><given-names>C.O.</given-names></name></person-group><article-title>Absence of vitamin D deficiency in young Nigerian children</article-title><source>J Pediatr</source><volume>133</volume><year>1998</year><fpage>740</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">9842036</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Thacher</surname><given-names>T.</given-names></name><name><surname>Fischer</surname><given-names>P.R.</given-names></name><name><surname>Pettifor</surname><given-names>J.</given-names></name><name><surname>Lawson</surname><given-names>J.</given-names></name><name><surname>Manaster</surname><given-names>B.</given-names></name><name><surname>Reading</surname><given-names>J.C.</given-names></name></person-group><article-title>Radiographic scoring method for the assessment of the severity of nutritional rickets</article-title><source>J Trop Pediatr</source><volume>46</volume><year>2000</year><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">10893912</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="book" id="rf0030"><person-group person-group-type="author"><name><surname>Prynne</surname><given-names>C.</given-names></name><name><surname>Paul</surname><given-names>A.A.</given-names></name></person-group><chapter-title>Food composition table for use in the Gambia</chapter-title><year>2007</year><publisher-name>MRC Human Nutrition Research</publisher-name><publisher-loc>Cambridge</publisher-loc></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Prynne</surname><given-names>C.</given-names></name><name><surname>Paul</surname><given-names>A.A.</given-names></name><name><surname>Dibba</surname><given-names>B.</given-names></name><name><surname>Jarjou</surname><given-names>L.M.</given-names></name></person-group><article-title>Gambian food records: a new framework for computer coding</article-title><source>J Food Compos Anal</source><volume>15</volume><year>2002</year><fpage>349</fpage><lpage>357</lpage></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>A.</given-names></name><name><surname>Bates</surname><given-names>C.J.</given-names></name></person-group><article-title>An appraisal of the adequacy of dietary mineral intakes in developing countries for bone growth and development in children</article-title><source>Nutr Rev</source><volume>6</volume><year>1993</year><fpage>51</fpage><lpage>69</lpage></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Kemi</surname><given-names>V.E.</given-names></name><name><surname>Karkkainen</surname><given-names>M.U.</given-names></name><name><surname>Rita</surname><given-names>H.J.</given-names></name><name><surname>Laaksonen</surname><given-names>M.J.</given-names></name><name><surname>Outila</surname><given-names>T.A.</given-names></name><name><surname>Lamberg-Allardt</surname><given-names>C.J.</given-names></name></person-group><article-title>Low calcium:phosphorus ratio in habitual diets affects serum parathyroid hormone concentration and calcium metabolism in healthy women with adequate calcium intake</article-title><source>Br J Nutr</source><volume>103</volume><year>2010</year><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">19781123</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><mixed-citation publication-type="other">Department of Health. Dietary reference values for food energy and nutrients for the United Kingdom. In: Committee on Medical Aspects of Food Policy. Report on Health and Social Subjects No 49, London: HMSO; 1991, p. xxiv.</mixed-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>A.</given-names></name><name><surname>Goldberg</surname><given-names>G.R.</given-names></name><name><surname>Schoenmakers</surname><given-names>I.</given-names></name></person-group><article-title>Vitamin D across the lifecycle: physiology and biomarkers</article-title><source>Am J Clin Nutr</source><volume>88</volume><year>2008</year><fpage>500S</fpage><lpage>506S</lpage><pub-id pub-id-type="pmid">18689390</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>J.</given-names></name><name><surname>Fiddy</surname><given-names>J.</given-names></name><name><surname>Payne</surname><given-names>R.</given-names></name></person-group><article-title>Adjustment of serum total calcium for albumin concentration: effects of non-linearity and of regression differences between laboratories</article-title><source>Ann Clin Biochem</source><volume>33</volume><year>1996</year><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">8929068</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Mosteller</surname><given-names>R.</given-names></name></person-group><article-title>Simplified calculation of body-surface area</article-title><source>N Engl J Med</source><volume>317</volume><year>1987</year><fpage>1098</fpage><pub-id pub-id-type="pmid">3657876</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="book" id="rf0125"><person-group person-group-type="author"><name><surname>Grubb</surname><given-names>A.O.</given-names></name></person-group><chapter-title>Cystatin C &#x02014; properties and use as diagnostic marker</chapter-title><person-group person-group-type="editor"><name><surname>Spiegel</surname><given-names>H.E.</given-names></name></person-group><series>Adv Clin Chem.</series><year>2001</year><publisher-name>Elsevier</publisher-name><publisher-loc>San Diego</publisher-loc><fpage>72</fpage><lpage>84</lpage></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>G.</given-names></name><name><surname>Munoz</surname><given-names>A.</given-names></name><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Mak</surname><given-names>R.</given-names></name><name><surname>Kaskel</surname><given-names>F.</given-names></name><name><surname>Warady</surname><given-names>B.</given-names></name></person-group><article-title>New equations to estimate GFR in children with CKD</article-title><source>JASN</source><volume>30</volume><year>2009</year><fpage>629</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">19158356</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>G.</given-names></name><name><surname>Brion</surname><given-names>L.</given-names></name><name><surname>Spitzer</surname><given-names>A.</given-names></name></person-group><article-title>The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents</article-title><source>Pediatr Clin North Am</source><volume>34</volume><year>1987</year><fpage>571</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">3588043</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="book" id="rf0070"><person-group person-group-type="author"><name><surname>Nordin</surname><given-names>B.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name></person-group><chapter-title>Diagnostic procedures in disorders of calcium metabolism</chapter-title><year>1965</year><publisher-name>J. A. Churchill Ltd.</publisher-name><publisher-loc>London</publisher-loc></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>R.</given-names></name></person-group><article-title>Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation</article-title><source>Ann Clin Biochem</source><volume>35</volume><year>1998</year><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">9547891</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>A.</given-names></name><name><surname>Laskey</surname><given-names>M.A.</given-names></name><name><surname>Shaw</surname><given-names>J.</given-names></name><name><surname>Hudson</surname><given-names>G.J.</given-names></name><name><surname>Day</surname><given-names>K.C.</given-names></name><name><surname>Jarlou</surname><given-names>L.M.A.</given-names></name></person-group><article-title>The calcium and phosphorus intakes of rural Gambian women during pregnancy and lactation</article-title><source>Br J Nutr</source><volume>69</volume><year>1993</year><fpage>885</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">8329362</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>L.</given-names></name></person-group><article-title>Calcium bioavailability and absorption: a review</article-title><source>Am J Clin Nutr</source><volume>35</volume><year>1982</year><fpage>783</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">7041607</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>R.D.</given-names></name><name><surname>Madias</surname><given-names>N.E.</given-names></name><name><surname>Levey</surname><given-names>A.S.</given-names></name></person-group><article-title>Serum creatinine as an index of renal function: new insights into old concepts</article-title><source>Clin Chem</source><volume>38</volume><year>1992</year><fpage>1933</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">1394976</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Herget-Rosenthal</surname><given-names>S.</given-names></name><name><surname>Boekenkamp</surname><given-names>A.</given-names></name><name><surname>Hofmann</surname><given-names>W.</given-names></name></person-group><article-title>How to estimate GFR-serum creatinine, serum cystatin C or equations?</article-title><source>Clin Biochem</source><volume>40</volume><year>2007</year><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">17234172</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Dharnidharka</surname><given-names>V.R.</given-names></name><name><surname>Kwon</surname><given-names>C.</given-names></name><name><surname>Stevens</surname><given-names>G.</given-names></name></person-group><article-title>Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis</article-title><source>Am J Kidney Dis</source><volume>40</volume><year>2002</year><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">12148093</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>C.P.</given-names></name><name><surname>Cox</surname><given-names>S.E.</given-names></name><name><surname>Fulford</surname><given-names>A.J.</given-names></name><name><surname>Austin</surname><given-names>S.</given-names></name><name><surname>Hilmers</surname><given-names>D.C.</given-names></name><name><surname>Abrams</surname><given-names>S.A.</given-names></name></person-group><article-title>Iron incorporation and post-malaria anaemia</article-title><source>PLoS One</source><volume>3</volume><year>2008</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>B.H.</given-names></name><name><surname>Joseph</surname><given-names>F.</given-names></name><name><surname>Bailey</surname><given-names>L.M.</given-names></name><name><surname>Fraser</surname><given-names>W.D.</given-names></name></person-group><article-title>The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays</article-title><source>Ann Clin Biochem</source><volume>44</volume><year>2007</year><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">17761032</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Schouten</surname><given-names>B.J.</given-names></name><name><surname>Hunt</surname><given-names>P.J.</given-names></name><name><surname>Livesey</surname><given-names>J.H.</given-names></name><name><surname>Frampton</surname><given-names>C.M.</given-names></name><name><surname>Soule</surname><given-names>S.G.</given-names></name></person-group><article-title>FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study</article-title><source>JCEM</source><volume>94</volume><year>2009</year><fpage>2332</fpage><lpage>2337</lpage><pub-id pub-id-type="pmid">19366850</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Oduwole</surname><given-names>A.O.</given-names></name><name><surname>Giwa</surname><given-names>O.S.</given-names></name><name><surname>Arogundade</surname><given-names>R.A.</given-names></name></person-group><article-title>Relationship between rickets and incomplete distal renal tubular acidosis in children</article-title><source>Ital J Pediatr</source><volume>36</volume><year>2010</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20180944</pub-id></element-citation></ref></ref-list><ack><title>Acknowledgments</title><p>The work was performed at MRC Human Nutrition Research, Cambridge, UK and MRC Keneba, The Gambia and supported by the <funding-source id="gts0005">UK Medical Research Council</funding-source> [Unit Programme numbers U105960371 and U123261351]. We would like to thank the clinical, scientific and field staff of MRC Keneba, especially Dr Stephen Owens, Dr Tony Fulford (MRC International Nutrition Group) for his statistical advice, Dr Shailja Nigdikar, Ms Janet Bennett, Ms Ann Laidlaw, Ms Duangporn Harnpanich and Ms Jennifer Thompson (HNR), for their valuable assistance, and all the subjects for their participation.</p></ack><fn-group><fn id="d32e2064"><label>&#x02606;</label><p>Funding source: Medical Research Council, UK.</p></fn><fn id="d32e2069"><label>&#x02606;&#x02606;</label><p>Prior Publication: Oral presentation at ECTS PhD Training Conference, Berlin, September 2010. Poster presentation at BRS/BORS 3rd Joint Meeting, Cambridge, June 2011.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig.&#x000a0;1</label><caption><p>A. FGF23 concentrations of rickets follow-up children (RFU) (<inline-graphic xlink:href="fx1.gif"/>) and local community children (<inline-graphic xlink:href="fx2.gif"/>) and mean and SEM. The unadjusted 2-sample Student's&#x000a0;<italic>t</italic>-test is p&#x000a0;=&#x000a0;0.26. 19% of RFU have [FGF23]&#x000a0;&#x0003e;&#x000a0;125&#x000a0;RU/ml, 3% of LC have [FGF23]&#x000a0;&#x0003e;&#x000a0;125&#x000a0;RU/ml (&#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;3.67, p&#x000a0;=&#x000a0;0.03). B. lnFGF23 of RFU at follow-up plotted against lnFGF23 at presentation. Broken line indicates the upper-limit assay reference range of 125&#x000a0;RU/ml. The equation of the line is lnFGF23 (RFU)&#x000a0;=&#x000a0;&#x02212;&#x000a0;0.3&#x000a0;+&#x000a0;0.7lnFGF23 (presentation), R<sup>2</sup>&#x000a0;=&#x000a0;57.4% (p&#x000a0;&#x02264;&#x000a0;0.0001) (unadjusted for age).</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig.&#x000a0;2</label><caption><p>Relationship between lnHb and lnFGF23 in rickets follow-up children (RFU) (A) and local community children (LC) (B). Age adjusted linear regression equations for RFU and LC children are lnFGF23&#x000a0;=&#x000a0;19.2&#x02013;6.0 lnHb&#x000a0;+&#x000a0;0.03 Age, R<sup>2</sup>&#x000a0;=&#x000a0;19.5% (p&#x000a0;=&#x000a0;0.01) and lnFGF23&#x000a0;=&#x000a0;0.43&#x000a0;+&#x000a0;1.47 lnHb&#x000a0;&#x02212;&#x000a0;0.03 Age, R<sup>2</sup>&#x000a0;=&#x000a0;4.8% (p&#x000a0;=&#x000a0;0.3) respectively. There is a significant lnHb&#x000a0;&#x000d7;&#x000a0;group interaction (p&#x000a0;=&#x000a0;0.003).</p></caption><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig.&#x000a0;3</label><caption><p>Proposed mechanism relating rickets to urinary phosphate wasting caused by a chronically low calcium intake (reproduced from <xref rid="bb0010" ref-type="bibr">[2]</xref>).</p></caption><graphic xlink:href="gr3"/></fig><table-wrap id="t0005" position="float"><label>Table&#x000a0;1</label><caption><p>Dietary assessment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left">Dietary intake per day</th><th colspan="3" align="center">RFU children <italic>n&#x000a0;=&#x000a0;35</italic><hr/></th><th colspan="3" align="center">LC children <italic>n&#x000a0;=&#x000a0;29</italic><hr/></th><th colspan="2" align="center">SDS<hr/></th></tr><tr><th align="left">6.0&#x02013;9.9&#x000a0;years<hr/></th><th align="left">10.0&#x02013;13.9&#x000a0;years<hr/></th><th align="left">14.0&#x02013;22.0&#x000a0;years<hr/></th><th align="left">6.0&#x02013;9.9&#x000a0;years<hr/></th><th align="left">10.0&#x02013;13.9&#x000a0;years<hr/></th><th align="left">14.0&#x02013;18.0&#x000a0;years<hr/></th><th rowspan="2" align="left">RFU-SDS</th><th align="left"><italic>p</italic>-value<hr/></th></tr><tr><th align="left"><italic>n&#x000a0;=&#x000a0;29</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;4</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;2</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;9</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;10</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;10</italic></th><th align="left">RFU v LC</th></tr></thead><tbody><tr><td align="left">Calcium (mg)*</td><td align="left">182 (119, 279)</td><td align="left">208 (143, 304)</td><td align="left">233 (164, 332)</td><td align="left">217 (116, 406)</td><td align="left">471 (334, 665)</td><td align="left">268 (151, 474)</td><td align="left">&#x02212;&#x000a0;0.52 (0.98)</td><td align="left"><bold>0.04</bold></td></tr><tr><td align="left">Phosphorus (mg)*</td><td align="left">543 (381, 774)</td><td align="left">631 (554, 718)</td><td align="left">696 (587, 825)</td><td align="left">501 (312, 804)</td><td align="left">769 (584, 1,013)</td><td align="left">647 (404, 1,037)</td><td align="right">0.07 (0.75)</td><td align="left">0.7</td></tr><tr><td align="left">Ca/P (mmol/mmol)</td><td align="left">0.27 (0.08)</td><td align="left">0.26 (0.09)</td><td align="left">0.26 (0.04)</td><td align="left">0.34 (0.10)</td><td align="left">0.49 (0.15)</td><td align="left">0.32 (0.05)</td><td align="left">&#x02212;&#x000a0;0.80 (0.82)</td><td align="left"><bold>0.0008</bold></td></tr><tr><td align="left">Energy (kJ)</td><td align="left">5560 (1637)</td><td align="left">7395 (853)</td><td align="left">8105 (442)</td><td align="left">5,864 (2179)</td><td align="left">7086 (1815)</td><td align="left">7473 (2701)</td><td align="left">&#x02212;&#x000a0;0.08 (0.70)</td><td align="left">0.7</td></tr><tr><td align="left">Protein (g)</td><td align="left">12.5 (1.8)</td><td align="left">11.1 (1.3)</td><td align="left">10.9 (0.1)</td><td align="left">36.6 (13.3)</td><td align="left">50.7 (10.1)</td><td align="left">51.8 (23.1)</td><td align="left">&#x02212;&#x000a0;0.29 (0.88)</td><td align="left">0.2</td></tr><tr><td align="left">Fibre (g)</td><td align="left">27.5 (7.9)</td><td align="left">34.6 (3.8)</td><td align="left">38.0 (15.2)</td><td align="left">31.8 (12.1)</td><td align="left">41.9 (11.6)</td><td align="left">40.5 (17.2)</td><td align="left">&#x02212;&#x000a0;0.07 (1.31)</td><td align="left">0.8</td></tr><tr><td align="left">Phytate (g)*</td><td align="left">0.72 (0.48, 1.09)</td><td align="left">0.84 (0.65, 1.09)</td><td align="left">0.73 (0.55, 0.97)</td><td align="left">0.72 (0.45, 1.16)</td><td align="left">0.98 (0.64, 1.49)</td><td align="left">0.89 (0.52, 1.52)</td><td align="left">&#x02212;&#x000a0;0.05 (0.83)</td><td align="left">0.8</td></tr></tbody></table><table-wrap-foot><fn><p>For normally distributed data, the results are mean (SD); for positively skewed data (denoted by *) the results are geometric mean (&#x02212;&#x000a0;1SD, +&#x000a0;SD). The children are grouped into RFU children (rickets follow-up children) and LC children (local community children) and are then subdivided into age groups. <italic>n</italic>&#x000a0;=&#x000a0;number of children with data available. RFU-SDS (standard deviation scores) are mean (SD) and are calculated by [value <sub>RFU</sub>&#x000a0;&#x02212;&#x000a0;mean<sub>LC</sub>)&#x000a0;/&#x000a0;SD<sub>LC</sub>]. <italic>p</italic>-value RFU v LC indicates the 2-sample Student's&#x000a0;<italic>t</italic>-test <italic>p</italic>-value (RFU SDS/LC SDS).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table&#x000a0;2</label><caption><p>Blood biochemistry.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left">Fasting blood sample</th><th colspan="3" align="center">RFU children <italic>n&#x000a0;=&#x000a0;34</italic><hr/></th><th colspan="3" align="center">LC children <italic>n&#x000a0;=&#x000a0;30</italic><hr/></th><th colspan="2" align="center">SDS<hr/></th></tr><tr><th align="left">6.0&#x02013;9.9&#x000a0;years<hr/></th><th align="left">10.0&#x02013;13.9&#x000a0;years<hr/></th><th align="left">14.0&#x02013;22.0&#x000a0;years<hr/></th><th align="left">6.0&#x02013;9.9&#x000a0;years<hr/></th><th align="left">10.0&#x02013;13.9&#x000a0;years<hr/></th><th align="left">14.0&#x02013;18.0&#x000a0;years<hr/></th><th rowspan="2" align="left">RFU-SDS</th><th align="left"><italic>p</italic>-value<hr/></th></tr><tr><th align="left">n&#x000a0;=&#x000a0;27</th><th align="left">n&#x000a0;=&#x000a0;5</th><th align="left">n&#x000a0;=&#x000a0;2</th><th align="left">n&#x000a0;=&#x000a0;10</th><th align="left">n&#x000a0;=&#x000a0;10</th><th align="left">n&#x000a0;=&#x000a0;10</th><th align="left">RFU v LC</th></tr></thead><tbody><tr><td align="left">25OHD (nmol/l)</td><td align="left">61 (14)</td><td align="left">57 (12)</td><td align="left">67 (12)</td><td align="left">61 (17)</td><td align="left">52 (18)</td><td align="left">46 (16)</td><td align="char">0.12 (0.86)</td><td align="left">0.6</td></tr><tr><td align="left">Corr-Ca (mmol/l)</td><td align="left">2.28 (0.08)</td><td align="left">2.29 (0.06)</td><td align="left">2.27 (0.03)</td><td align="left">2.33 (0.04)</td><td align="left">2.34 (0.07)</td><td align="left">2.34 (0.06)</td><td align="char">&#x02212;&#x000a0;0.97 (1.32)</td><td align="left"><bold>0.002</bold></td></tr><tr><td align="left">iCa (mmol/l)</td><td align="left">1.13 (0.04)</td><td align="left">1.14 (0.02)</td><td align="left">1.16 (0.05)</td><td align="left">1.14 (0.03)</td><td align="left">1.15 (0.03)</td><td align="left">1.14 (0.04)</td><td align="char">&#x02212;&#x000a0;0.33 (1.32)</td><td align="left">0.2</td></tr><tr><td align="left">P (mmol/l)</td><td align="left">1.53 (0.13)</td><td align="left">1.51 (0.23)</td><td align="left">1.06 (0.06)</td><td align="left">1.59 (0.20)</td><td align="left">1.41 (0.21)</td><td align="left">1.45 (0.18)</td><td align="char">&#x02212;&#x000a0;0.27 (0.87)</td><td align="left">0.2</td></tr><tr><td align="left">FGF23 (RU/ml)*</td><td align="left">65 (19, 223)</td><td align="left">54 (8, 392)</td><td align="left">63 (61, 65)</td><td align="left">54 (38, 76)</td><td align="left">39 (22, 69)</td><td align="left">49 (19, 125)</td><td align="char">0.54 (3.33)</td><td align="left">0.4</td></tr><tr><td align="left">1,25(OH)<sub>2</sub>D (pmol/l)*</td><td align="left">246 (192, 315)</td><td align="left">323 (181, 578 )</td><td align="left">247 (196, 317)</td><td align="left">236 (187,298)</td><td align="left">265 (197, 356)</td><td align="left">287 (224, 368)</td><td align="char">0.20 (1.21)</td><td align="left">0.5</td></tr><tr><td align="left">TALP (U/l)*</td><td align="left">299 (243, 369)</td><td align="left">332 (273, 405)</td><td align="left">133 (132, 133)</td><td align="left">280 (220, 356)</td><td align="left">264 (204, 342)</td><td align="left">252 (190, 335)</td><td align="char">0.21 (1.05)</td><td align="left">0.4</td></tr><tr><td align="left">PTH (pg/ml)*</td><td align="left">34.9 (12.7, 96.1)</td><td align="left">60.6 (39.7, 92.6)</td><td align="left">46.8 (45.8, 47.9)</td><td align="left">45.5 (29.4, 70.3)</td><td align="left">65.5 (40.5, 105.9)</td><td align="left">66.0 (44.2, 98.5)</td><td align="char">&#x02212;&#x000a0;0.55 (2.01)</td><td align="left">0.2</td></tr><tr><td align="left">Albumin (g/l)</td><td align="left">39.9 (2.5)</td><td align="left">39.1 (4.5)</td><td align="left">39.6 (0.3)</td><td align="left">37.8 (2.9)</td><td align="left">35.7 (3.5)</td><td align="left">36.8 (2.1)</td><td align="char">0.78 (0.90)</td><td align="left"><bold>0.001</bold></td></tr><tr><td align="left">AST (U/l)*</td><td align="left">34.5 (26.4, 45.3)</td><td align="left">25.3 (17.7, 36.1)</td><td align="left">23.8 (20.1, 28.5)</td><td align="left">24.9 (19.9, 30.9)</td><td align="left">25.0 (17.9, 34.8)</td><td align="left">20.0 (15.6, 25.8)</td><td align="char">1.68 (2.06)</td><td align="left"><bold>0.0002</bold></td></tr><tr><td align="left">Bilirubin (&#x003bc;mol/l)*</td><td align="left">5.3 (3.6, 7.8)</td><td align="left">6.8 (5.4, 8.5)</td><td align="left">12.7 (4.6, 35.3)</td><td align="left">8.2 (6.6, 10.2)</td><td align="left">7.6 (5.1, 11.3)</td><td align="left">10.8 (6.7, 17.2)</td><td align="char">&#x02212;&#x000a0;1.63 (1.83)</td><td align="left"><bold>0.0001</bold></td></tr><tr><td align="left">Cys C (mg/l)*</td><td align="left">0.85 (0.75, 0.96)</td><td align="left">0.79 (0.71, 0.87)</td><td align="left">0.80 (0.69, 0.92)</td><td align="left">0.78 (0.70, 0.87)</td><td align="left">0.76 (0.65, 0.88)</td><td align="left">0.80 (0.69, 0.93)</td><td align="char">0.58 (1.04)</td><td align="left"><bold>0.02</bold></td></tr><tr><td align="left">Cr (&#x003bc;mol/l)</td><td align="left">53.4 (5.1)</td><td align="left">56.6 (5.0)</td><td align="left">67.9 (4.4)</td><td align="left">52.4 (5.0)</td><td align="left">59.9 (5.7)</td><td align="left">64.0 (8.3)</td><td align="char">0.09 (1.00)</td><td align="left">0.7</td></tr><tr><td align="left">Hb (g/dl)</td><td align="left">12.6 (1.16)</td><td align="left">13.1 (1.5)</td><td align="left">13.5 (0.3)</td><td align="left">12.4 (1.3)</td><td align="left">12.9 (1.4)</td><td align="left">13.5 (1.2)</td><td align="char">0.21 (0.88)</td><td align="left">0.3</td></tr><tr><td align="left">cAMP (pmol/ml)*</td><td align="left">38.9 (26.2, 57.9)</td><td align="left">48.1 (20.8, 111.0)</td><td align="left">31.6 (27.2, 36.8)</td><td align="left">61.5 (39.2, 95.6)</td><td align="left">68.5 (40.1, 116.9)</td><td align="left">60.7 (46.3, 79.6)</td><td align="char">&#x02212;&#x000a0;1.04 (1.02)</td><td align="left"><bold>0.0001</bold></td></tr><tr><td align="left">Mg (mmol/l)</td><td align="left">0.86 (0.05)</td><td align="left">0.78 (0.06)</td><td align="left">0.73 (0.03)</td><td align="left">0.85 (0.06)</td><td align="left">0.84 (0.05)</td><td align="left">0.85 (0.03)</td><td align="char">&#x02212;&#x000a0;0.20 (1.34)</td><td align="left">0.5</td></tr></tbody></table><table-wrap-foot><fn><p>For normally distributed data, the results are mean (SD); for positively skewed data (denoted by *) the results are geometric mean (&#x02212;&#x000a0;1SD, +&#x000a0;SD). The children are grouped into RFU children (rickets follow-up children) and LC children (local community children) and are then subdivided into age groups. <italic>n</italic>&#x000a0;=&#x000a0;number of children with data available. RFU-SDS (standard deviation scores) are mean (SD) and are calculated by [value <sub>RFU</sub>&#x000a0;&#x02212;&#x000a0;mean<sub>LC</sub>)&#x000a0;/&#x000a0;SD<sub>LC</sub>]. <italic>p</italic>-value RFU v LC indicates the 2-sample Student's&#x000a0;<italic>t</italic>-test <italic>p</italic>-value (RFU SDS/LC SDS).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0015" position="float"><label>Table&#x000a0;3</label><caption><p>eGFR and mineral clearance.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left">eGFR and mineral clearance</th><th colspan="3" align="center">RFU children n&#x000a0;=&#x000a0;33<hr/></th><th colspan="3" align="center">LC children n&#x000a0;=&#x000a0;30<hr/></th><th colspan="2" align="center">SDS<hr/></th></tr><tr><th align="left">6.0&#x02013;9.9&#x000a0;years<hr/></th><th align="left">10.0&#x02013;13.9&#x000a0;years<hr/></th><th align="left">14.0&#x02013;22.0&#x000a0;years<hr/></th><th align="left">6.0&#x02013;9.9&#x000a0;years<hr/></th><th align="left">10.0&#x02013;13.9&#x000a0;years<hr/></th><th align="left">14.0&#x02013;18.0&#x000a0;years<hr/></th><th rowspan="2" align="left">RFU-SDS</th><th align="left">p-value<hr/></th></tr><tr><th align="left"><italic>n&#x000a0;=&#x000a0;26</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;5</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;2</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;10</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;10</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;10</italic></th><th align="left"><italic>RFU v LC</italic></th></tr></thead><tbody><tr><td colspan="9" align="left"><italic>eGFR</italic></td></tr><tr><td align="left">Cys C-eGFR</td><td align="left">93.7 (16.3)</td><td align="left">103.2 (15.0)</td><td align="left">101.7 (20)</td><td align="left">104.1 (16.1)</td><td align="left">109.9 (24.6)</td><td align="left">101.3 (20.9)</td><td align="char">&#x02212;&#x000a0;0.55 (0.96)</td><td align="left"><bold>0.03</bold></td></tr><tr><td align="left">C-B-eGFR</td><td align="left">95.3 (8.1)</td><td align="left">100.3 (14.1)</td><td align="left">102.7 (8.0)</td><td align="left">99.2 (6.4)</td><td align="left">110.8 (7.5)</td><td align="left">111.5 (12.5)</td><td align="char">&#x02212;&#x000a0;0.74 (1.35)</td><td align="left"><bold>0.01</bold></td></tr><tr><td align="left">Schwarz-eGFR</td><td align="left">109.9 (9.7)</td><td align="left">117.6 (11.7)</td><td align="left">120.0 (0.4)</td><td align="left">111.1 (6.0)</td><td align="left">118.3 (47.4)</td><td align="left">138.5 (28.0)</td><td align="char">&#x02212;&#x000a0;0.19 (1.44)</td><td align="left">0.5</td></tr><tr><td align="left">C<sub>Cr</sub> (&#x003bc;mol/min)* <sup>B</sup></td><td align="left">0.53 (0.32, 0.85)</td><td align="left">0.56 (0.22, 1.43)</td><td align="left">0.69 (0.64, 0.75)</td><td align="left">0.46 (0.31, 0.69)</td><td align="left">0.54 (0.39, 0.74)</td><td align="left">0.70 (3.84, 1.27)</td><td align="char">0.27 (1.48)</td><td align="left">0.4</td></tr><tr><td colspan="9" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="9" align="left"><italic>2&#x000a0;h urinary collection</italic></td></tr><tr><td align="left">P (mmol/2&#x000a0;h) * <sup>B</sup></td><td align="left">0.68 (0.38, 1.21)</td><td align="left">0.54 (0.15, 1.97)</td><td align="left">0.68 (0.32, 1.42)</td><td align="left">0.48 (0.23, 0.96)</td><td align="left">0.46 (0.21, 0.98)</td><td align="left">0.54 (0.25, 1.12)</td><td align="char">0.44 (0.95)</td><td align="left">0.07</td></tr><tr><td align="left">C<sub>P</sub> (mmol/min) <sup>B</sup></td><td align="left">0.004 (0.003)</td><td align="left">0.005 (0.003)</td><td align="left">0.006 (0.004)</td><td align="left">0.003 (0.002)</td><td align="left">0.003 (0.001)</td><td align="left">0.003 (0.002)</td><td align="char">0.54 (1.33)</td><td align="left">0.07</td></tr><tr><td align="left">TmP:GFR <sup>B</sup></td><td align="left">1.60 (0.23)</td><td align="left">1.85 (0.33)</td><td align="left">1.06 (0.20)</td><td align="left">1.88 (0.45)</td><td align="left">1.63 (0.33)</td><td align="left">1.67 (0.36)</td><td align="char">&#x02212;&#x000a0;0.48 (0.81)</td><td align="left"><bold>0.04</bold></td></tr><tr><td align="left">Ca (mmol/2&#x000a0;h)* <sup>B</sup></td><td align="left">0.03 (0.008, 0.10)</td><td align="left">0.02 (0.005, 0.12)</td><td align="left">0.15 (0.04, 0.52)</td><td align="left">0.02 (0.003, 0.16)</td><td align="left">0.04 (0.02, 0.11)</td><td align="left">0.06 (0.02, 0.12)</td><td align="char">0.07 (0.99)</td><td align="left">0.8</td></tr><tr><td align="left">C<sub>Ca</sub> (nmol/min)* <sup>B</sup></td><td align="left">0.09 (0.02, 0.10)</td><td align="left">0.10 (0.04, 0.55)</td><td align="left">0.50 (0.13, 1.73)</td><td align="left">0.09 (0.02, 0.35)</td><td align="left">0.16 (0.06, 0.36)</td><td align="left">0.24 (0.14, 0.44)</td><td align="char">&#x02212;&#x000a0;0.03 (1.08)</td><td align="left">0.9</td></tr><tr><td colspan="9" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="9" align="left"><italic>24&#x000a0;h urinary collection</italic></td></tr><tr><td align="left">P (mmol/24&#x000a0;h)* <sup>B</sup></td><td align="left">6.2 (3.9, 9.7)</td><td align="left">8.9 (6.7, 11.9)</td><td align="left">7.4 <sup>n=1</sup></td><td align="left">4.4 (2.6, 7.5)</td><td align="left">8.4 (5.3, 13.4)</td><td align="left">11.9 (9.1, 15.6)</td><td align="char">0.48 (0.93)</td><td align="left"><bold>0.05</bold></td></tr><tr><td align="left">C<sub>P</sub> (mmol/min) <sup>B</sup></td><td align="left">0.003 (0.001)</td><td align="left">0.004 (0.002)</td><td align="left">0.004<sup>n=1</sup></td><td align="left">0.002 (0.001)</td><td align="left">0.004 (0.002)</td><td align="left">0.006 (0.001)</td><td align="char">0.60 (1.05)</td><td align="left"><bold>0.02</bold></td></tr><tr><td align="left">Ca (mmol/24&#x000a0;h)* <sup>B</sup></td><td align="left">0.40 (0.12, 1.35)</td><td align="left">0.61 (0.22, 1.69)</td><td align="left">1.97<sup>n=1</sup></td><td align="left">0.83 (0.36, 1.89)</td><td align="left">0.64 (0.18, 2.20)</td><td align="left">0.57 (0.22, 1.43)</td><td align="char">&#x02212;&#x000a0;0.69 (1.44)</td><td align="left"><bold>0.03</bold></td></tr><tr><td align="left">C<sub>Ca</sub> (nmol/min) * <sup>B</sup></td><td align="left">0.12 (0.03, 0.43)</td><td align="left">0.19 (0.04, 0.74)</td><td align="left">0.65 (0.18, 2.23)</td><td align="left">0.24 (0.10, 0.55)</td><td align="left">0.16 (0.04, 0.53)</td><td align="left">0.19 (0.09, 0.44)</td><td align="char">&#x02212;&#x000a0;0.55 (1.60)</td><td align="left">0.1</td></tr></tbody></table><table-wrap-foot><fn><p>For normally distributed data, the results are mean (SD); for positively skewed data (denoted by *) the results are geometric mean (&#x02212;&#x000a0;1SD, +&#x000a0;SD). The children are grouped into RFU children (rickets follow-up children) and LC children (local community children) and are then subdivided into age groups. <italic>n</italic>&#x000a0;=&#x000a0;number of children with data available. RFU-SDS (standard deviation scores) are mean (SD) and are calculated by [value <sub>RFU</sub>&#x000a0;&#x02212;&#x000a0;mean<sub>LC</sub>)&#x000a0;/&#x000a0;SD<sub>LC</sub>]. <italic>p</italic>-value RFU v LC indicates 2-sample Student's&#x000a0;<italic>t</italic>-test <italic>p</italic>-value (RFU SDS/LC SDS). eGFR (estimated glomerular filtration rate), Cys C (cystatin C), C&#x02013;B (Counahn&#x02013;Barret), C<sub>Cr</sub> (creatinine clearance in mmol/min over 2&#x000a0;h), C<sub>P</sub> (phosphate clearance in mmol/min &#x02014; 2&#x000a0;h), TmP:GFR (tubular maximum reabsorption of phosphate in mmol/l), C<sub>Ca</sub> (calcium clearance in nmol/min &#x02014; 2&#x000a0;h), C<sub>P</sub> (phosphate clearance in mmol/min &#x02014; 24&#x000a0;h) and C<sub>Ca</sub> (calcium clearance in nmol/min &#x02014; 24&#x000a0;h). <sup>B</sup>Indicates variables corrected to an age-appropriate body surface area (BSA<sub>age</sub>) as calculated by mean BSA per LC age band.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0020" position="float"><label>Table&#x000a0;4</label><caption><p>Profile of RFU children with and without lasting leg deformities.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left">Follow-up</th><th colspan="2" align="center">SDS<hr/></th><th align="center"><italic>p-value</italic><hr/></th></tr><tr><th align="left">Deformity<hr/></th><th align="left">No deformity<hr/></th><th align="left">No deformity</th></tr><tr><th align="left"><italic>n&#x000a0;=&#x000a0;19</italic></th><th align="left"><italic>n&#x000a0;=&#x000a0;16</italic></th><th align="left">v deformity</th></tr></thead><tbody><tr><td colspan="4" align="left"><italic>Dietary intake per day</italic></td></tr><tr><td align="left">Calcium (mg)</td><td align="char">&#x02212;&#x000a0;0.48 (0.90)</td><td align="char">&#x02212;&#x000a0;0.51 (1.15)</td><td align="left">0.9</td></tr><tr><td align="left">Phosphorus (mg)</td><td align="char">&#x02212;&#x000a0;0.01 (0.69)</td><td align="char">0.21 (0.83)</td><td align="left">0.4</td></tr><tr><td align="left">Ca/P (mmol/mmol)</td><td align="char"><bold>&#x02212;&#x000a0;0.80 (0.83)</bold></td><td align="char"><bold>&#x02212;&#x000a0;0.71 (0.87)</bold></td><td align="left">0.8</td></tr><tr><td align="left">Energy (kJ)</td><td align="char">&#x02212;&#x000a0;0.13 (0.75)</td><td align="char">0.06 (0.65)</td><td align="left">0.4</td></tr><tr><td align="left">Protein (g)</td><td align="char">0.23 (0.87)</td><td align="char">0.42 (0.93)</td><td align="left">0.6</td></tr><tr><td align="left">Fibre (g)</td><td align="char">&#x02212;&#x000a0;0.27 (1.12)</td><td align="char">0.38 (1.50)</td><td align="left">0.2</td></tr><tr><td align="left">Phytate (g)</td><td align="char">&#x02212;&#x000a0;0.08 (0.84)</td><td align="char">0.07 (0.88)</td><td align="left">0.6</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>Fasting blood sample</italic></td></tr><tr><td align="left">25OHD (nmol/l)</td><td align="char">0.11 (0.85)</td><td align="char">0.13 (0.91)</td><td align="left">0.9</td></tr><tr><td align="left">Corr-Ca (mmol/l)</td><td align="char"><bold>&#x02212;&#x000a0;0.77 (1.13)</bold></td><td align="char"><bold>&#x02212;&#x000a0;1.18 (1.50)</bold></td><td align="left">0.4</td></tr><tr><td align="left">iCa (mmol/l)</td><td align="char">&#x02212;&#x000a0;0.46 (0.99)</td><td align="char">&#x02212;&#x000a0;0.18 (1.63)</td><td align="left">0.6</td></tr><tr><td align="left">P (mmol/l)</td><td align="char">&#x02212;&#x000a0;0.25 (0.91)</td><td align="char">&#x02212;&#x000a0;0.30 (0.86)</td><td align="left">0.9</td></tr><tr><td align="left">FGF23 (RU/ml)</td><td align="char">1.24 (3.99)</td><td align="char">&#x02212;&#x000a0;0.26 (2.25)</td><td align="left">0.2</td></tr><tr><td align="left">1,25(OH)<sub>2</sub>D (pmol/l)</td><td align="char">0.61 (1.32)</td><td align="char">&#x02212;&#x000a0;0.26 (0.88)</td><td align="left"><bold>0.03</bold></td></tr><tr><td align="left">TALP (U/l)</td><td align="char">0.30 (0.92)</td><td align="char">0.11 (1.20)</td><td align="left">0.6</td></tr><tr><td align="left">PTH (pg/ml)</td><td align="char">0.01 (1.71)</td><td align="char">&#x02212;&#x000a0;1.19 (2.34)</td><td align="left">0.1</td></tr><tr><td align="left">Albumin (g/l)</td><td align="char"><bold>0.79 (1.01)</bold></td><td align="char"><bold>0.77 (0.80)</bold></td><td align="left">0.9</td></tr><tr><td align="left">AST (U/l)</td><td align="char"><bold>1.94 (1.86)</bold></td><td align="char"><bold>1.38 (2.29)</bold></td><td align="left">0.4</td></tr><tr><td align="left">Bilirubin (&#x003bc;mol/l)</td><td align="char"><bold>&#x02212;&#x000a0;2.33 (1.84)</bold></td><td align="char"><bold>&#x02212;&#x000a0;0.83 (1.50)</bold></td><td align="left"><bold>0.01</bold></td></tr><tr><td align="left">Cys C (mg/l)</td><td align="char"><bold>0.96 (0.85)</bold></td><td align="char">0.16 (1.10)</td><td align="left"><bold>0.02</bold></td></tr><tr><td align="left">Cr (&#x003bc;mol/l)</td><td align="char">0.25 (1.05)</td><td align="char">&#x02212;&#x000a0;0.07 (0.94)</td><td align="left">0.3</td></tr><tr><td align="left">Hb (g/dl)</td><td align="char">&#x02212;&#x000a0;0.01 (0.73)</td><td align="char">0.37 (1.03)</td><td align="left">0.2</td></tr><tr><td align="left">cAMP (pmol/ml)</td><td align="char"><bold>&#x02212;&#x000a0;1.14 (0.56)</bold></td><td align="char">&#x02212;&#x000a0;<bold>0.93 (1.39)</bold></td><td align="left">0.6</td></tr><tr><td align="left">Mg (mmol/l)</td><td align="char">0.29 (1.36)</td><td align="char"><bold>&#x02212;&#x000a0;0.76 (1.12)</bold></td><td align="left"><bold>0.03</bold></td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>eGFR</italic></td></tr><tr><td align="left">Cys C eGFR</td><td align="char"><bold>&#x02212;&#x000a0;0.91 (0.72)</bold></td><td align="char">&#x02212;&#x000a0;0.14 (1.05)</td><td align="left"><bold>0.02</bold></td></tr><tr><td align="left">C-B eGFR</td><td align="char"><bold>&#x02212;&#x000a0;1.01 (1.17)</bold></td><td align="char">&#x02212;&#x000a0;0.44 (1.49)</td><td align="left">0.2</td></tr><tr><td align="left">C<sub>Cr</sub> (&#x003bc;mol/min) <sup>B</sup></td><td align="char">0.32 (1.23)</td><td align="char">0.21 (1.74)</td><td align="left">0.8</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>2&#x000a0;h urinary collection</italic></td></tr><tr><td align="left">P (mmol/2&#x000a0;h) <sup>B</sup></td><td align="char"><bold>0.58 (0.71)</bold></td><td align="char">0.30 (1.17)</td><td align="left">0.4</td></tr><tr><td align="left">C<sub>P</sub> (mmol/min) <sup>B</sup></td><td align="char">0.52 (1.02)</td><td align="char">0.55 (1.64)</td><td align="left">0.9</td></tr><tr><td align="left">TmP:GFR<sup>B</sup></td><td align="char"><bold>&#x02212;&#x000a0;0.58 (0.90)</bold></td><td align="char">&#x02212;&#x000a0;0.37 (0.70)</td><td align="left">0.5</td></tr><tr><td align="left">Ca (mmol/2&#x000a0;h) <sup>B</sup></td><td align="char">0.03 (1.06)</td><td align="char">0.12 (0.93)</td><td align="left">0.8</td></tr><tr><td align="left">C<sub>Ca</sub> (nmol/min) <sup>B</sup></td><td align="char">&#x02212;&#x000a0;0.11 (1.24)</td><td align="char">0.06 (0.92)</td><td align="left">0.7</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="4" align="left"><italic>24&#x000a0;h urinary collection</italic></td></tr><tr><td align="left">P (mmol/24&#x000a0;h) <sup>B</sup></td><td align="char">0.39 (1.02)</td><td align="char"><bold>0.60 (0.82)</bold></td><td align="left">0.5</td></tr><tr><td align="left">C<sub>P</sub> (mmol/min) <sup>B</sup></td><td align="char">0.53 (1.12)</td><td align="char"><bold>0.68 (0.99)</bold></td><td align="left">0.7</td></tr><tr><td align="left">Ca (mmol/24&#x000a0;h) <sup>B</sup></td><td align="char">&#x02212;&#x000a0;0.63 (1.69)</td><td align="char"><bold>&#x02212;&#x000a0;0.76 (1.09)</bold></td><td align="left">0.8</td></tr><tr><td align="left">C<sub>Ca</sub> (nmol/min) <sup>B</sup></td><td align="char">&#x02212;&#x000a0;0.83 (1.92)</td><td align="char">&#x02212;&#x000a0;0.27 (1.19)</td><td align="left">0.6</td></tr></tbody></table><table-wrap-foot><fn><p>SD-score (as calculated by (value <sub>RFU</sub>&#x000a0;&#x02212;&#x000a0;mean<sub>LC</sub>)&#x000a0;/&#x000a0;SD<sub>LC</sub>) with LC age bands) and 1&#x000a0;SD of RFU with and without lasting deformity.</p><p><italic>p-value</italic> indicates 2-sample Student's&#x000a0;<italic>t</italic>-test p-value between RFU with and without deformity. SDS in bold indicates p&#x000a0;&#x02264;&#x000a0;0.05 between RFU group and LC. eGFR (estimated glomerular filtration rate), Cys C (cystatin C), C-B (Counahn&#x02013;Barret), C<sub>Cr</sub> (creatinine clearance in mmol/min over 2&#x000a0;h), C<sub>P</sub> (phosphate clearance in mmol/min &#x02014; 2&#x000a0;h), TmP:GFR (tubular maximum reabsorption of phosphate in mmol/l), C<sub>Ca</sub> (calcium clearance in nmol/min &#x02014; 2&#x000a0;h), C<sub>P</sub> (phosphate clearance in mmol/min &#x02014; 24&#x000a0;h) and C<sub>Ca</sub> (calcium clearance in nmol/min &#x02014; 24&#x000a0;h). <sup>B</sup>Indicates variables corrected to an age-appropriate body surface area (BSA<sub>age</sub>) as calculated by mean BSA per LC age band.</p></fn></table-wrap-foot></table-wrap></floats-group></article>